• Positive family histories suggest the existence of hereditary immune thrombocytopenia (ITP).
Essentials
• Positive family histories suggest the existence of hereditary immune thrombocytopenia (ITP).
• The predisposing gene for familial ITP was screened in two familial ITP patients.
• The G76S mutation on TNFRSF13B led to immune dysfunction and induced megakaryocyte apoptosis.
• The G76S mutation on TNFRSF13B is a gain-of-function mutation and a predisposing variant for ITP.
Summary. Background: Most immune thrombocytopenia (ITP) is sporadic but a positive family history of ITP in some patients suggests that hereditary forms exist. Because of the rarity of familial ITP families available for study and the heterogeneity of sporadic ITP, family linkage analysis or genome-wide association studies are limited. Objectives: Based on one ITP pedigree, we try to identify the predisposing gene in familial or sporadic ITP and reveal the way in which it causes thrombocytopenia. Methods: Gene expression profiling analysis and whole-exome sequencing were performed on samples from family members with ITP, sporadic ITP cases and healthy individuals. We also evaluated the influence of potential pathogenic mutation on immune function and megakaryocyte apoptosis. Results: Whole-exome sequencing identified a potential pathologic p.G76S heterozygous mutation on the TNFRSF13B gene in familial ITP patients. ITP patients harboring the G76S mutation displayed an upregulated 'cytokine-cytokine receptor interaction' signal, increased serum TNFa, IL-17a, IFNc and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells. Additionally, Epstein-Barr virus (EBV)-transformed B cells with the G76S mutation could induce
Introduction
Immune thrombocytopenia (ITP) is a common bleeding disorder with autoimmune features. Most ITP is sporadic but a positive family history of ITP in some patients suggests that hereditary forms exist. Rischewski's group described data from the Pediatric and Adult Registry on Chronic ITP (PARC-ITP), and found that 10 of 445 (2.2%) pediatric ITP cases had a positive familial history of ITP, suggesting an existence of genetic susceptibility to ITP [1] . Because of the rarity of familial ITP families available for study and the heterogeneity of sporadic ITP, family linkage analysis or genome-wide association studies are limited. Many studies to examine candidate genes for ITP have focused on immune-related genes for which there is evidence of perturbation in ITP or other autoimmune disorders. Several DNA polymorphisms are considered genetic risk factors for ITP [2] and contribute, at least partly, to the elucidation of pathogenesis of ITP. The TNFRSF13B gene encodes the transmembrane activator and CAML interactor (TACI), a B-cell receptor. TNFRSF13B gene mutations have been identified in common variable immunodeficiency (CVID) [3] [4] [5] , and ITP is not uncommon in CVID (10%) and is frequently the first manifestation of the disease [6] . TACI is expressed on mature B cells, and its activation causes Tcell-dependent or independent responses. Emmerich's group reported that TNFSF13B promoter polymorphisms (-871 T/C) in ITP patients are associated with increased serum B cell-activating factor (BAFF), suggesting that TACI signaling might be involved in the pathogenesis of ITP [7] . Here, we identified a heterozygous germline mutation in the TNFRSF13B gene in family members with ITP. The mutation causing the G76S amino acid substitutions enhanced APRIL (a proliferation-inducing ligand encoded by TNFSF13B) binding and increased serum cytokines. The mutation also had pro-apoptotic potential in human megakaryocytes. The association of ITP with the TNFRSF13B mutation was evaluated in 112 cases of sporadic ITP (2.68%) and 233 controls (0.86%). Data show that the TNFRSF13B mutation is a high-risk genetic factor for familial or sporadic ITP.
Case reports

Case 1
A 16-year-old woman was diagnosed with ITP in October of 2007. A platelet count at that time was 4 9 10 9 L
À1
, and white blood cell (WBC) count and hemoglobin were normal. Findings from a bone marrow evaluation were consistent with ITP. She responded well to prednisone (1 mg kg À1 day À1 ) and intravenous immunoglobulins (IVIg) (0.4 g kg À1 day À1 ). However, her platelet count decreased again after termination of treatment for 2 weeks and fluctuated at levels of 14-24 9 10 9 L À1 . The patient's sister had been suffering from ITP since the age of 5 years (referred Case 2). Her father and mother had no medical problems and did not show any bleeding tendency in daily life. No positive signs or symptoms of autoimmune diseases and liver disorders were found or recorded. The proband's grandfather had died from hepatocellular carcinoma 15 years ago, and her grandmother was still living, and apparently healthy without any bleeding phenotype. The pedigree in the affected family is shown in Fig. 1(A) . The complete blood counts (including platelet count) of the proband's parents were in the normal range. However, the proband's father is a smoker. ) when the dose of glucocorticoids was reduced. On 30 October 2014, the patient was admitted to the hospital for severe headaches. Platelets were 9 9 10 9 L À1 and a brain CT revealed a right frontal lobe hematoma. The patient promptly fell into a coma. After platelet transfusion, high-dose IVIg and methylprednisolone infusion, an emergency removal of the intracranial hematoma was performed. There was also a vascular malformation inside the hematoma on the right frontal lobe with a massive hemorrhage. Three days after surgery the patient died of a cerebral hernia.
Case 2
A 5-year-old female, the younger sister of case 1, was diagnosed with ITP in January of 2011. After that, she presented with repeated dermal petechia and ecchymosis with lowest platelets count of 7 9 10 9 L
À1
. She was given prednisone at regular intervals and often her platelets would rise to normal, but chiefly they fluctuated at 20-70 9 10 9 L À1 . She was referred to our department in Quantile normalization and subsequent data processing were performed using the GeneSpring GX v11.5 software package (Agilent Technologies). After quantile normalization of the raw data, genes with at least eight of 10 samples having flags were chosen for data analysis. Differentially expressed genes between two samples were identified through fold-change filtering (≥ 2.0). Pathway analysis was performed with gene mapping to KEGG pathways (P < 0.05). Pathway and GO analyses were applied to determine roles of differentially expressed genes in these biological pathways or GO terms. Finally, hierarchical clustering was used to distinguish gene expression among samples.
Real-time quantitative PCR assay for differentially expressed genes
Total RNA was extracted from peripheral blood mononuclear cells (PBMCs) from two family members with ITP (Cases 1 and 2), four sporadic ITP cases and two healthy controls using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Then 2 lg RNA was reverse-transcribed into cDNA using the Revert Aid First Strand cDNA synthesis kit (Fermentas, Vilnius, Lithuania). Transcribed cDNA was amplified using a SYBR Green I PCR reagent (Takara, Shiga, Japan). Primers for CCL3, CCL13, INHBE, TNFb (LTA), CXCL2, CCL3L3 and IL-31RS-b (OSMR) genes were synthesized by the BoShang Biotechnology Company, Shang Hai, China. The primers sequence data are available upon request.
Whole-exome capture and sequencing
For the two probands and their parents, high-molecularweight genomic DNA was extracted from freshly frozen PBMCs. For each DNA sample, whole-exome capture was accomplished based on liquid phase hybridization of sonicated genomic DNA to the bait cRNA library, which was synthesized on magnetic beads using the SureSelect Human All Exon V5 kit (Agilent Technology), according to the manufacturer's protocol. Captured targets were subjected to massively parallel sequencing using HiSeq2000 with the paired-end 100 bp read option, according to the manufacturer's instructions. BWA software was used to align paired-end reads to the reference human genome (hg19, downloaded from http://genome.uc sc.edu/) with default parameters. After alignment, only uniquely mapped reads or confidently mapped paired-end reads were kept. Variations including SNVs and indels were identified with the Samtools software package and filtered with recommended thresholds for cases.
Mutation frequencies in sporadic ITP samples and healthy controls
We analyzed the TNFRSF13B G76S variant using PCR product sequencing in 233 population-based healthy controls (94 male; median age of 31 years) and 112 patients with sporadic ITP (40 male; median age of 38 years), including 52 patients newly diagnosed with ITP, 16 with persistent ITP and 44 with chronic ITP. ITP categorization was based on the criteria for ITP diagnosis from an international working group [8] . To determine whether sporadic ITP with G76S mutation was secondary to CVID, immunoglobulin G (IgG), IgA and IgM were measured and a diagnosis of CVID was excluded [9, 10] . (TNFa) and 1.8 pg mL À1 (IFNc).
TACI expression assay
PBMCs of ITP patients or healthy controls were separated from peripheral blood using Ficoll (GE Healthcare, Uppsala, Sweden) density centrifugation. TACI expression on CD19 + B cells from PBMCs and EBV-transformed B cells was assayed with PE-labeled rat anti-human TACI antibody (BD Pharmingen, San Diego, CA, USA), followed by PerCp-labeled anti-human CD19 antibody (BD Pharmingen) or appropriate PE-labeled isotype controls. At least 1 9 10 4 live cells were acquired, gated according to forward and sideward scatters, and analyzed on a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA) using FlowJo software (TreeStar, Ashland, OR, USA). ) and probed with APC-labeled polyclonal goat anti-human APRIL antibody (R & D Systems, Minneapolis, MN, USA) or the appropriate APC-labeled isotype controls with PerCp-labeled antihuman CD19 antibody (BD Pharmingen). At least 1 9 10 4 cells, gated according to the forward and sideward scatters were collected and analyzed on a FACSCalibur using FlowJo software (TreeStar).
Co-culture assay of megakaryocytes and B lymphocytes
To explore whether the TNFRSF13B G76S mutation influences apoptosis of human megakaryoblastic cells (Meg-01), a Transwell co-culture system was established and in each six-well plate with a 0.4-lm aperture (Corning, New York, NY, USA), Meg-01 cells and EBV-transformed B-cell lines from ITP patients or healthy individuals with or without the TNFRSF13B G76S mutation were co-cultured (1 : 1). In the culture system, Meg-01 cells were placed on the bottom and EBV-transformed B cells on the upper level. After co-culture for 96 h, Meg-01 cells were harvested and apoptosis was measured using an annexin V-FITC/PI apoptosis kit (Becton Dickinson) with flow cytometry.
Statistical analysis
Comparisons between patient groups with TNFRSF13B mutations and healthy controls with TNFRSF13B mutations were analyzed for statistical significance with chi-squared testing. Genotypes were compared using a Fisher's exact test and were performed, along with odds ratios (ORs) and 95% confidence interval (CI) calculations, with SPSS 17.0 software. Comparisons between groups were made with one-way ANOVA or a Mann-Whitney Utest. Differences were considered significant at P < 0.05.
Results
Familial ITP gene expression signature in signal transductional pathways analysis
Compared with all other samples (four sporadic ITP cases, two healthy controls and the proband's parents), the gene expression in the two familial ITP patients mainly involved cytokine-cytokine receptor interaction or complement and coagulation cascade signaling pathways (Table 1) and displayed an increased tendency. When compared with four sporadic ITP patients, upregulated signals in the two familial ITP patients were enriched in 11 of the signaling pathways, as indicated in Table 2 . Analysis of cytokine-cytokine receptor interaction-related genes using hierarchical clustering indicated that familial ITP patients had upregulated expression of six genes, as shown in Figs 2 and 3.
Discovery of mutations through exome sequencing
We captured and sequenced exomes from the two familial ITP patients and their parents with PBMCs. Samtools software was used to identify somatic mutations by comparing variants identified in PBMC exome datasets against dbSNP; 723 potential somatic sequence changes were identified. We focused our analysis on changes predicted to affect cytokine-cytokine interaction pathways and identified the p.Gly76Ser mutation in TNFRSF13B.
To validate this, we amplified the corresponding coding region from original samples using PCR and carried out Sanger sequencing. We observed that the two familial ITP patients and their father harbored heterozygous G76S mutations in the TNFRSF13B gene (Fig. 1B.) . To determine whether the G76S mutation was a germline mutation, we extracted DNA from oral mucosa cells and Sanger sequencing showed that both familial patients and their father carried the G76S germline mutation, but the familial patients' mother did not. A search for the mutation in 233 population-based healthy controls and 112 sporadic ITP cases revealed that of those sporadic ITP cases, three had heterozygous G76S mutations (2.68%) in the TNFRSF13B gene. However, in healthy controls the incidence of G76S mutations was 0.86% (2/233). Interestingly, sequencing on DNA samples of oral mucosa cells and PBMCs from one sporadic ITP patient and one healthy individual showed that both of them harbored germline and somatic G76S mutations on the TNFRSF13B gene. In databases of known polymorphisms using the Exome Aggregation Consortium, the incidence of the G76S mutation is 0.0001815 (from 60 706 normal population data points). Compared with healthy individuals, the incidence of G76S mutations in sporadic ITP cases was not significantly higher (P = 0.334) and the odds ratio was 3.18 (95% CI, 0.52-19.30). However, when combining familial ITP cases (n = 2) with sporadic ITP cases harboring G76S mutations (n = 3), the mutation rate of G76S in ITP reached 4.39% (5/114) and was significantly higher than that in healthy individuals (P = 0.04 with odds ratio 5.30; 95% CI, 1.01-27.74), indicating that TNFRSF13B G76S is a disease-related mutation in ITP.
G76S mutations enhance TNFRSF13B mRNA and protein expression
To assess the effects of G76S mutations on TNFRSF13B mRNA and protein expression, we performed real-time quantitative PCR (RT-qPCR) and antibody-binding experiments on PBMCs. RT-qPCR results showed that TNFRSF13B mRNA in five ITP patients with the G76S mutation (including two familial ITP patients and three sporadic ITP cases) was significantly higher than in 10 sporadic ITP cases or 10 healthy controls without the G76S mutation. These data are in Fig. 4(A) . We measured TNFRSF13B protein (TACI) expression on B cells and EBV-transformed B cells from individuals with the G76S mutation and sporadic ITP or healthy controls without this mutation using flow cytometry. Five cases with the G76S mutation (including two familial ITP patients and three sporadic ITP cases) had a higher percentage of TACI expression on CD19 + B cells from PBMCs (93.83% AE 6.56%). However, in sporadic ITP cases (n = 10) and healthy controls (n = 10) without G76S mutation the percentage of TACI expression was 58.01% AE 13.59% and 56.1% AE 18.19%, respectively. Compared with sporadic ITP cases and healthy controls, the statistical difference was very significant (P = 0.002 and P = 0.001, respectively) (Fig. 4B) . Similar to the results from PBMCs, TACI expression on EBV-transformed B cells was significantly upregulated in ITP cases with the G76S mutation when compared with that in ITP patients or healthy controls without G76S mutation (Fig. 4C) . These data agreed with changes in TNFRSF13B mRNA expression, suggesting that the G76S mutation was a gain-of-function mutation. 
G76S mutation upregulates serum immune inflammatory factors
As shown in Fig. 5(A) , serum BAFF, IL-17a, TNFa and IFNc in five ITP patients with the G76S mutation (two familial ITP patients and three sporadic ITP cases) were elevated significantly, compared with sporadic ITP patients (n = 10) or healthy individuals (n = 10) without G76S mutations (P < 0.05), suggesting that increased immune cytokines contribute to T-cell-mediated thrombocytopenia in patients with TNFRSF13B mutations.
The G76S mutation facilitates APRIL binding
To reveal if the G76S mutation influences receptor-ligand interactions, we tested the APRIL-binding capability on CD19 + B cells from PBMCs or EBV-transformed B-cell lines. As shown in Fig. 5(B and C) , the APRIL binding rate was 88.83% AE 3.23% in group 1 (including two familial ITP patients and three sporadic ITP cases with the G76S mutation), whereas in group 2 (10 sporadic ITP cases without the G76S mutation) and group 3 (10 healthy individuals without the G76S mutation) the APRIL-binding rates were 40.89% AE 21.50% and 43.31% AE 18.71%, respectively. The statistical analysis showed there was a significant difference between group 1 and group 2 (P = 0.001), and group 1 and group 3 (P = 0.002), suggesting the G76S mutation may enhance APRIL binding in TACI and the G76S mutation is a mutation of the gain of function.
EBV-transformed B lymphocytes with the G76S mutation have the potential to promote apoptosis of megakaryocytes As shown in Fig. 6 , when EBV-transformed B cells from subjects with the G76S mutation were co-cultured with Meg-01 cells for 96 h, apoptotic Meg-01 cells increased. Compared with normal or sporadic ITP subjects without the G76S mutation, the differences were statistically significant (P < 0.05), indicating that the G76S TNFRSF13B mutation can facilitate megakaryocyte apoptosis. 
Discussion
Using whole exome sequencing for familial ITP members, we identified G76S mutations in the TNFRSF13B gene in two familial ITP cases and determined that the mutation was of germline origin. Subsequently, we screened three non-familial ITP cases harboring a G76S mutation and 112 patients with sporadic ITP. All variations were heterozygous mutations. The distribution frequency in local healthy individuals with the G76S mutation was low, suggesting that the G76S mutation is a disease-associated mutation and that there is a genetic susceptibility to ITP.
TACI encoded by TNFRSF13B [11] is expressed on peripheral B cells and can bind B-cell-activating factor (BAFF) or APRIL to regulate survival and apoptosis of immune cells [12, 13] . It has been shown that Tnfrsf13b in vitro. In vivo antigen challenge resulted in enhanced antigen-specific antibody production [14] . A subsequent study confirmed that Tnfrsf13b À/À mice might develop fatal autoimmune glomerulonephritis, proteinurea and elevated levels of circulating autoantibodies, including anti-dsDNA and anti-nuclear autoantibodies. In addition, treatment of B cells with TACI agonistic antibodies inhibits proliferation in vitro, and activation of a chimeric receptor containing the TACI intracellular domain induces apoptosis. These results demonstrate the critical role of TACI in regulation of B-cell homeostasis [15] . Our cases did not display any evidence of splenomegaly or renal impairment. The paradoxical phenotypes may be related to the site or extent of the involved Tnfrsf13b gene. In Tnfrsf13b TACI [14] , whereas the mutation of TACI in our cases is localized in the N-terminal cysteine-rich domain 2 (CRD2), which is situated in the extracellular domain. Another explanation is that Tnfrsf13b À/À manifests as loss of function, whereas the mutation in our case is geared towards gain of function. In human individuals, TNFRSF13B mutation-related disorders are involved in CVID [3] [4] [5] , and we excluded CVID in our case series. There is evidence that the TNFRSF13B mutation coincided with ITP in a few patients with CVID, suggesting that the mutation predisposes people to ITP [16] . However, this ITP, as a manifestation, is a component of CVID. Our cases carrying the G76S mutation have ITP and no CVID-related symptoms, including hypoimmunoglobulinemia, susceptibility to infection and splenomegaly. Consequently, TNFRSF13B mutations are associated with a broader spectrum of diseases, and are not only restricted to CVID. Compared with Zhang's reported CVID with thrombocytopenia [16] , the mutational loci in TNFRSF13B is different. The G76S is localized in the N-terminal cysteine-rich domain 2 (CRD2) [16] and for CVID cases complicated by ITP, the mutational locus is mainly in CRD2 (C104R:4/6) and the transmembrane region (TM) (A181E:2/6), suggesting that different mutations in the same gene have different clinical phenotypes and pathogenic mechanisms.
For heterozygous G76S mutations, the clinical presentation in family members ranges from unaffected (proband's father) to severe ITP (proband 1). The variable penetrances of TNFRSF13B mutations in humans may reflect partial functional redundancy of the APRIL-BAFF-BAFFR-TACI-BCMA axis. Furthermore, a combination of genetic, environmental and lifestyle factors may interfere with the genotype-phenotype relationship. In our cases, this phenotypic difference might be explained in part by the sex or age differences. Whether female patients carrying the G76S mutation are more predisposed to thrombocytopenia than male patients carrying the same mutation remains to be further clarified by accumulated cases.
The role of the TNFRSF13B mutation in sporadic ITP is unclear, and the observation that mutations in TNFRSF13B are associated with ITP suggests that TACI signaling is also important for normal B-cell or T-cell function. Gene expression profiling results showed familial ITP members had upregulated cytokine-cytokine receptor interaction signaling compared with sporadic ITP, and most of these signaling pathways (9/11) are involved in immune regulation or autoimmune disorders ( Table 2 ). Data showed that CCL3, CCL13, INHBE, TNFb, CXCL2, CCL3L3 and IL31RSb genes were overexpressed in familial ITP (Fig. 2) . Most results (apart from INHBE) were confirmed with RT-qPCR analysis (Fig. 3) , suggesting that TACI G76S mutations are positive regulators of 'cytokine-cytokine receptor interaction'-related genes.
The TACI receptor is composed of trimers or higher order oligomers; the effect of a heterozygous mutation would depend on the complex assembly, ligand binding and a sufficient number of functioning receptors [11, 17] . TACI is expressed on mature B cells and its activation leads to T cell-dependent or independent responses [18] . We show that the G76S heterozygous mutation in cells of five subjects with ITP produces increased TACI protein expression and this is consistent with mRNA changes. More importantly, PBMCs or EBV-transformed B cells from ITP patients with the G76S mutation have enhanced capacity to bind to APRIL, suggesting that this mutation is a gain-of-function mutation, and amplifies the humoral immunity effects in ITP. Studies show that CD8 + T cell-induced lysis of platelets in chronic ITP may be involved in the pathogenesis of this disorder [19] . In the current study, we found that ITP patients with G76S mutations had increased serum T-cell activating markers, including IL-17a, TNFa, IFNc and BAFF. Therefore, we could not rule out the possibility that TACI-mediated CD8 + T cell activation or its secretary factors were involved in the pathogenesis of ITP or immune thrombocyte lysis.
In vitro studies indicate that autoantibodies against platelet glycoproteins are found in ITP plasma, and megakaryocyte production and maturation are under this influence [20, 21] . De Botton's group reported that proplatelet formation was a consequence of local caspase activation during megakaryocyte differentiation, suggesting increased megakaryocyte apoptosis may contribute to ITP [22] . Recently, Goette and colleagues confirmed that increased platelet apoptosis occurs in adult ITP, and antibody-dependent cell cytotoxicity in platelets may be an underlying mechanism for ITP [23] . However, these observations are inconsistent with the results of Hou's group, who stated that ITP plasma may boost megakaryocyte counts and impaired megakaryocyte maturation [24] . This difference may be explained by different megakaryocyte sources [25] . In the present work, we developed a co-culture system to evaluate whether B cells with the G76S mutation could trigger megakaryocyte apoptosis. Although Meg-01 cells are derived from human megakaryoblastic leukemia cells, Meg-01 cells spontaneously release platelet-sized particles and are suitable for the study of thrombopoiesis [22] . Our results showed that the G76S mutation could induce Meg-01 cell apoptosis significantly. Thus, we infer that G76S mutation-driven thrombocytopenia is partly attributed to the pro-apoptotic effect of B cells bearing the G76S mutation, but how this occurs is unclear. Thus, we report that the TNFRSF13B G76S mutation is a genetic risk factor for ITP and is a gain-of-function mutation with increased TNFRSF13B mRNA and protein expression, enhanced APRIL binding and activated T-cell secretory products. G76S mutations are involved in the regulation of cytokine-cytokine receptor interaction signaling. Immune dysfunction may also contribute to the pathogenesis of ITP. Increased megakaryocyte apoptosis in ITP individuals harboring the G76S mutation may partly explain the clinical phenotype of ITP, but more studies are needed to clarify a causal relation between genetic factors and ITP. 
